描述癌症治愈之路的中位数和里程碑：讲述“故事”。 - Suppr

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

作者信息

Hellmann Matthew D, Kris Mark G, Rudin Charles M

机构信息

Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York2Weill Cornell Medical College, New York, New York.

出版信息

JAMA Oncol. 2016 Feb;2(2):167-8. doi: 10.1001/jamaoncol.2015.4345.

DOI:10.1001/jamaoncol.2015.4345

PMID:26583516

Abstract

摘要

相似文献

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

JAMA Oncol. 2016 Feb;2(2):167-8. doi: 10.1001/jamaoncol.2015.4345.

Mixed response and time-to-event endpoints for multistage single-arm phase II design.

Trials. 2015 Jun 4;16:250. doi: 10.1186/s13063-015-0743-9.

Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.

J Biopharm Stat. 2016;26(1):141-9. doi: 10.1080/10543406.2015.1092030.

Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.

J Clin Oncol. 2009 Dec 10;27(35):5868-73. doi: 10.1200/JCO.2009.22.4162. Epub 2009 Oct 13.

Multiplicity in confirmatory clinical trials: a case study with discussion from a JSM panel.

Stat Med. 2015 Nov 20;34(26):3461-80. doi: 10.1002/sim.6561. Epub 2015 Jun 25.

Response Rate as an Approval End Point in Oncology: Back to the Future.

JAMA Oncol. 2016 Jun 1;2(6):780-1. doi: 10.1001/jamaoncol.2015.6352.

N-of-1 trials in oncology.

Lancet Oncol. 2015 Aug;16(8):885-6. doi: 10.1016/S1470-2045(15)00062-5.

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Oncologist. 2019 Nov;24(11):1469-1478. doi: 10.1634/theoncologist.2019-0175. Epub 2019 Jul 18.

Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?

J Clin Oncol. 2012 May 20;30(15):1750-4. doi: 10.1200/JCO.2011.38.6359. Epub 2012 Mar 5.

Joint modeling of clinical efficacy and safety with an application to diabetes studies.

J Biopharm Stat. 2013;23(5):1155-71. doi: 10.1080/10543406.2013.813520.

引用本文的文献

Beyond hazard ratios: appropriate statistical methods for quantifying the clinical effectiveness of immune-oncology therapies - the example of the Netherlands.

BMC Med Res Methodol. 2024 Oct 30;24(1):260. doi: 10.1186/s12874-024-02373-5.

Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.

EClinicalMedicine. 2023 Aug 9;63:102156. doi: 10.1016/j.eclinm.2023.102156. eCollection 2023 Sep.

Clinical outcomes of brain metastasectomy from soft tissue and bone sarcomas: a systematic review.

Int J Clin Oncol. 2022 Nov;27(11):1767-1779. doi: 10.1007/s10147-022-02227-4. Epub 2022 Aug 22.

Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials.

Front Oncol. 2022 Jul 14;12:892684. doi: 10.3389/fonc.2022.892684. eCollection 2022.

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.

PLoS One. 2021 Nov 15;16(11):e0258605. doi: 10.1371/journal.pone.0258605. eCollection 2021.

The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Front Oncol. 2021 Jul 21;11:671874. doi: 10.3389/fonc.2021.671874. eCollection 2021.

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.

Clinicians' Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study.

Adv Ther. 2019 Nov;36(11):3017-3029. doi: 10.1007/s12325-019-01099-x. Epub 2019 Oct 4.

Hypoxic Isolated Abdominal Perfusion (HAP) chemotherapy for non-operable advanced staged ovarian cancer with peritoneal carcinosis: an experience in 45 platinum-refractory ovarian cancer patients.

Indian J Surg Oncol. 2019 Sep;10(3):506-514. doi: 10.1007/s13193-019-00922-9. Epub 2019 Apr 16.

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Oncologist. 2019 Nov;24(11):1469-1478. doi: 10.1634/theoncologist.2019-0175. Epub 2019 Jul 18.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".

作者信息

机构信息

出版信息

相似文献

引用本文的文献